Identification of Patients with Ovarian Cancer Experiencing the Highest Benefit from Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study

Benoit You, Christopher Purdy, Larry J. Copeland, Elizabeth M. Swisher, Michael A. Bookman, Gini Fleming, Robert Coleman, Leslie M. Randall, Krishnansu S. Tewari, Bradley J. Monk, Robert S. Mannel, Joan L. Walker, Fabio Cappuccini, David Cohn, Mahvish Muzaffar, David Mutch, Andrea Wahner-Hendrickson, Lainie Martin, Olivier Colomban, Robert A. Burger

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'Identification of Patients with Ovarian Cancer Experiencing the Highest Benefit from Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study'. Together they form a unique fingerprint.

Medicine & Life Sciences